William Baker, MD
Internal Medicine · Bakersfield, CANPI 1720040793
Payments from drug & device makers
Across 585 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- GSK$1K
- AbbVie$817
- Johnson & Johnson$643
- Novartis$543
- AstraZeneca$508
- plus $4K from 35 others
What the payments were for
- Food & beverage$9,336100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 163 | $2,070 |
| GSK | 74 | $1,099 |
| AbbVie(2 entities) | 46 | $817 |
| Johnson & Johnson | 58 | $643 |
| Novartis | 32 | $543 |
| AstraZeneca | 32 | $508 |
| Pfizer | 27 | $415 |
| Merck | 18 | $376 |
| Radius Health, Inc. | 9 | $286 |
| Novo Nordisk | 15 | $254 |
| Bayer | 10 | $202 |
| Heartflow, Inc. | 3 | $191 |
| Philips North America LLC | 11 | $170 |
| Daiichi Sankyo Inc. | 8 | $158 |
| Lilly USA, LLC | 10 | $157 |
| Boehringer Ingelheim | 9 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $146 |
| Abbott | 3 | $135 |
| Nevro Corp. | 4 | $116 |
| Otsuka America Pharmaceutical, Inc. | 7 | $111 |
| Medtronic | 2 | $102 |
| Advanced Respiratory, Inc | 6 | $101 |
| Shield Therapeutics Inc | 4 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Lundbeck LLC | 2 | $46 |
| Dexcom, Inc. | 2 | $38 |
| Electromed, Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Biosense Webster, Inc. | 1 | $33 |
| Abiomed | 1 | $32 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $25 |
| Vertex | 1 | $24 |
| Pulmonx Corporation | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,341 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 205 | $173,885 |
| OzempicSemaglutide | 100 | $95,612 |
| JanuviaSitagliptin Phosphate | 119 | $94,271 |
| XareltoRivaroxaban | 101 | $84,724 |
| FarxigaDapagliflozin Propanediol | 100 | $81,146 |
| Repatha SureclickEvolocumab | 102 | $80,198 |
| JardianceEmpagliflozin | 79 | $78,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $68,866 |
| ProliaDenosumab | 34 | $56,979 |
| Repatha PushtronexEvolocumab | 45 | $33,981 |
| VascepaIcosapent Ethyl | 44 | $28,793 |
| NourianzIstradefylline | 12 | $25,795 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $22,792 |
| TrulicityDulaglutide | 16 | $19,756 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $415 | $173,885205 claims |
| MerckJanuvia, Janumet | $376 | $101,330132 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Jentadueto Xr | $157 | $99,648118 claims |
| Novo NordiskOzempic | $254 | $95,612100 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $508 | $94,894121 claims |
| Johnson & JohnsonXarelto, Invokana | $643 | $91,790113 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,099 | $85,292113 claims |
| AmgenProlia | $2,070 | $56,97934 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $157 | $31,10427 claims |
| BayerKerendia | $202 | $12,41620 claims |
| AbbVieSynthroid | $817 | $5,33858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Bakersfield
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.